Status: Not yet recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620
The goal of this study is to explore the safety, drug concentrations and effects on adrenal gland hormones after a single dose or multiple doses of OMS1620 in healthy participants. In addition, the effect of food on drug concentrations will also be tested.
Participants needed: 84
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: OMass Therapeutics Australia Proprietary LtdUpdated: Sep 9, 2026
Eligibility criteria
Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive) and weight ≥45.0 kg [+4]
Use of systemic glucocorticoid therapies within 3 months prior to Screening or u... [+3]